Shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) were down 8.8% during trading on Monday . The company traded as low as $16.76 and last traded at $16.93. Approximately 554,779 shares were traded during trading, a decline of 71% from the average daily volume of 1,946,501 shares. The stock had previously closed at $18.56.
Wall Street Analyst Weigh In
ADMA has been the topic of a number of recent analyst reports. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.
View Our Latest Report on ADMA Biologics
ADMA Biologics Stock Up 2.4 %
The company has a market cap of $3.95 billion, a P/E ratio of 59.68 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The business's fifty day moving average is $19.23 and its two-hundred day moving average is $17.23.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the firm posted $0.01 earnings per share. Equities analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current year.
Insiders Place Their Bets
In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.70% of the company's stock.
Hedge Funds Weigh In On ADMA Biologics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. USA Financial Formulas lifted its holdings in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. raised its position in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock worth $273,000 after acquiring an additional 888 shares in the last quarter. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth $30,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after purchasing an additional 1,509 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
